A Novel Adoptive Synthetic TCR and Antigen Receptor (STAR) T‐Cell Therapy for B‐Cell Acute Lymphoblastic Leukemia

Jiasheng Wang,Xian Zhang,Zhixiao Zhou,Yue Liu,Li Yu,Lemei Jia,Junfang Yang,Jingjing Li,Hanyang Yu,Wenzhong Li,Guangna Liu,Wei Rui,Hongli Zheng,Xueqiang Zhao,Xin Lin,Peihua Lu
DOI: https://doi.org/10.1002/ajh.26586
IF: 13.265
2022-05-03
American Journal of Hematology
Abstract:Background We developed a T‐cell‐receptor (TCR) complex‐based chimeric antigen receptor (CAR) named Synthetic TCR and Antigen Receptor (STAR). Here, we report pre‐clinical and phase I clinical trial data (NCT03953599) of this T cell therapy for refractory and relapsed (R/R) B cell acute lymphoblastic leukemia (B‐ALL) patients. Methods STAR consists of two protein modules each containing an antibody light or heavy chain variable region and TCR α or β chain constant region fused to the co‐stimulatory domain of OX40. T‐cells were transduced with a STAR‐OX40 lentiviral vector. A leukemia xenograft mouse model was used to assess the STAR/STAR‐OX40 T cell antitumor activity. Eighteen patients with R/R B‐ALL were enrolled into the clinical trial. Results In a xenograft mouse model, STAR‐T cells exhibited superior tumor‐specific cytotoxicity compared to conventional CAR‐T cells. Incorporating OX40 into STAR further improved the proliferation and persistence of tumor‐targeting T‐cells. In our clinical trial, 100% of patients achieved complete remission 4 weeks post‐STAR‐OX40 T‐cell infusion and 16/18 (88.9%) patients pursued consolidative allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Twelve of sixteen patients (75%) remained in leukemia‐free after a median follow‐up of 545 (433–665) days. The two patients without consolidative allo‐HSCT relapsed on Day 58 and Day 186. Mild cytokine release syndrome occurred in 10/18 (55.6%) patients and two patients experienced grade III neurotoxicity. Conclusions Our preclinical studies demonstrate super anti‐tumor potency of STAR‐OX40 T‐cells compared to conventional CAR‐T cells. The first‐in‐human clinical trial shows that STAR‐OX40 T cells are tolerable and an effective therapeutic platform for treating R/R B‐ALL. This article is protected by copyright. All rights reserved.
hematology
What problem does this paper attempt to address?